Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post Anti-PD-1 Melanoma”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)WithdrawnNCT03167177
What this trial is testing

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Who this might be right for
Melanoma
ImmunityBio, Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT05081609
What this trial is testing

Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more
Ascendis Pharma Oncology Division A/S 320
Testing effectiveness (Phase 2)Ended earlyNCT04455503
What this trial is testing

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Who this might be right for
Melanoma Stage IVMelanoma Stage III
Evaxion Biotech A/S 15
Testing effectiveness (Phase 2)UnknownNCT03917069
What this trial is testing

Nab-PCE vs PC for MM After Failure of Anti-PD-1

Who this might be right for
Advanced Melanoma
Peking University Cancer Hospital & Institute 145
Testing effectiveness (Phase 2)Active Not RecruitingNCT02743819
What this trial is testing

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Who this might be right for
Melanoma
University of Chicago 70
Large-scale testing (Phase 3)Active Not RecruitingNCT02362594
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 1,019
Early research (Phase 1)WithdrawnNCT03982134
What this trial is testing

PDR001 + Panobinostat for Melanoma and NSCLC

Who this might be right for
MelanomaNon Small Cell Lung Cancer
Muhammad Furqan
Early research (Phase 1)Study completedNCT03178851
What this trial is testing

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 155
Testing effectiveness (Phase 2)Ended earlyNCT05926960
What this trial is testing

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Pfizer 38
Large-scale testing (Phase 3)Active Not RecruitingNCT05608291
What this trial is testing

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Who this might be right for
Melanoma
Regeneron Pharmaceuticals 1,564